Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
modified-process recombinant hepatitis b vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The modified-process recombinant hepatitis B vaccine (mpHBV) is an investigational subunit vaccine developed by Merck & Co., Inc. as an optimized formulation of the existing RECOMBIVAX HB. It contains recombinant hepatitis B surface antigen (HBsAg) produced in yeast (*Saccharomyces cerevisiae*). The primary modification involves the use of a 2X phosphate-containing aluminum hydroxyphosphate sulfate adjuvant (2XP), designed to enhance the consistency and immunogenicity of the vaccine compared to the standard formulation. It has been evaluated in Phase 2 clinical trials for the prevention of hepatitis B virus infection in various populations, including neonates, healthy adults, and patients with renal insufficiency.
- Other names
- modified-process hepatitis B vaccine2XP hepatitis B vaccinempHBV
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on modified-process recombinant hepatitis b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on modified-process recombinant hepatitis b vaccine.